These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 22469218)
1. Benchmark dose analysis for Bacillus anthracis inhalation exposures in the nonhuman primate. Taft SC; Hines SA Risk Anal; 2012 Oct; 32(10):1750-68. PubMed ID: 22469218 [TBL] [Abstract][Full Text] [Related]
2. On the risk of mortality to primates exposed to anthrax spores. Haas CN Risk Anal; 2002 Apr; 22(2):189-93. PubMed ID: 12022669 [TBL] [Abstract][Full Text] [Related]
3. Addressing residual risk issues at anthrax cleanups: how clean is safe? Canter DA J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):1017-32. PubMed ID: 16020189 [TBL] [Abstract][Full Text] [Related]
4. Dose-Response Modeling for Inhalational Anthrax in Rabbits Following Single or Multiple Exposures. Gutting BW; Rukhin A; Marchette D; Mackie RS; Thran B Risk Anal; 2016 Nov; 36(11):2031-2038. PubMed ID: 26889937 [TBL] [Abstract][Full Text] [Related]
5. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664 [TBL] [Abstract][Full Text] [Related]
7. The benchmark dose method--review of available models, and recommendations for application in health risk assessment. Filipsson AF; Sand S; Nilsson J; Victorin K Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105 [TBL] [Abstract][Full Text] [Related]
15. Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center. Sanderson WT; Stoddard RR; Echt AS; Piacitelli CA; Kim D; Horan J; Davies MM; McCleery RE; Muller P; Schnorr TM; Ward EM; Hales TR J Appl Microbiol; 2004; 96(5):1048-56. PubMed ID: 15078521 [TBL] [Abstract][Full Text] [Related]
16. Modeling the incubation period of inhalational anthrax. Wilkening DA Med Decis Making; 2008; 28(4):593-605. PubMed ID: 18556642 [TBL] [Abstract][Full Text] [Related]
17. Interim guidelines for investigation of and response to Bacillus anthracis exposures. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):987-90. PubMed ID: 11724154 [TBL] [Abstract][Full Text] [Related]
18. An integrated experimental-computational approach for predicting virulence in New Zealand white rabbits and humans following inhalation exposure to Bacillus anthracis spores. Hess BM; Thomas DG; Weber TJ; Hutchison JR; Straub TM; Bruckner-Lea CJ; Powell JD; Kabilan S; Corley RA PLoS One; 2019; 14(7):e0219160. PubMed ID: 31260462 [TBL] [Abstract][Full Text] [Related]
19. A model for in-vivo delivered dose estimation for inhaled bacillus anthracis spores in humans with interspecies extrapolation. Weir MH; Haas CN Environ Sci Technol; 2011 Jul; 45(13):5828-33. PubMed ID: 21667964 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Inhaled Versus Deposited Dose Using the Exponential Dose-Response Model for Inhalational Anthrax in Nonhuman Primate, Rabbit, and Guinea Pig. Gutting BW; Rukhin A; Mackie RS; Marchette D; Thran B Risk Anal; 2015 May; 35(5):811-27. PubMed ID: 25545587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]